ARAbbey N. Ragan

Abbey N. Ragan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abbey N. Ragan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Direct N–SF5 and N–SF4CF3 Bond Formation through Strain-Release Functionalization of 3-Substituted [1.1.0]Azabicyclobutanes

    by Yannick Kraemer, Soojun Park, Wang-Yeuk Kong, Yongxin Chen, Anthony J. Witt, Jón Atiba Buldt, Abbey N. Ragan, Lauren M. Holder, Dean J. Tantillo, Cody Ross Pitts

    In comparison to modern methods for carbon–SF5 bond formation, methods for direct heteroatom–SF5 bond formation are exceptionally scarce, rendering motifs such as “N–SF5” virtually unexplored in the context of organic and medicinal chemistry. Herein, we demonstrate that direct N–SF5 bond formation can be accomplished through strain-release pentafluorosulfanylation of 3-aryl [1.1.0]azabicyclobutanes (ABBs), using an easy-to-access solution of SF5Cl. To our surprise, the resultant N–SF5 azetidines proved to be remarkably chemically stable and amenable to peripheral synthetic modifications (e.g., amination, cross-coupling, oxidation, dehalogenation, SN1, and SNAr reactions). The methodology also extends to direct N–SF4CF3 bond formation using trans-CF3SF4Cl, enabling comparative studies throughout this work. From a mechanistic standpoint, DFT calculations, Hammett analyses, and radical trapping experiments support our proposed radical chain propagation mechanism. From a fundamental standpoint, considering N–SF5 and N–SF4CF3 azetidines are heretofore unknown molecular motifs, this work analyzes their dynamic, spectroscopic, and crystallographic features, as well as computed properties (e.g., BDE and pKb values), to provide foundational knowledge and inform downstream applications. While the carbon-bound SF5 group has been employed as a bioisostere for a CF3 group, we posited the N–SF5 motif could be a potential replacement for a small sulfonamide. Ac-cordingly, we synthesized an N–SF5 derivative of a spleen tyrosine kinase inhibitor reported in the patent literature for comparative ADME studies; results from in vitro profiling indicate that an N–SF5 azetidine could indeed be an alternative for an N–SO2Me azetidine, in instances where enhanced lipophilicity is desirable.


  • Open Access

    Strain-Release Pentafluorosulfanylation of [1.1.0]Bicyclobutanes: An Entryway to Achiral SF5-Cyclobutanes

    by Yannick Kraemer, Jón Buldt, Alexander Stephens, Wang-Yeuk Kong, Abbey Ragan, Zane Haidar, Ansh Patel, James Fettinger, Dean Tantillo, Cody Pitts

    The first assortment of achiral pentafluorosulfanylated cyclobutanes (SF5-CBs) are now synthetically accessible through strain-release functionalization of [1.1.0]bicyclobutanes (BCBs) using SF5Cl. Methods for both chloropentafluorosulfanylation and hydropentafluorosulfanylation of BCBs are detailed herein, as well as proof-of-concept that the logic extends to tetrafluoro(aryl)sulfanylation, tetrafluoro(trifluoromethyl)sulfanylation, and iodopentafluorosulfanyl-ation. Considering the SF5 group and CBs have been employed as nonclassical bioisosteres, structural aspects of these unique SF5-CB “hybrid isosteres” were also studied using SC-XRD. Ostensibly, the reaction proceeds through a curious polarity mismatch addition of SF5 radicals to the electrophilic sites of the BCBs. The nature of the C(sp3)–SF5 bond formation step was studied and contextualized using DFT calculations.